Immediate in-hospital reactivation of patients with an exacerbation of Chronic Obstructive Pulmonary Disease (COPD): Pulmofit-MST

ISRCTN ISRCTN99715969
DOI https://doi.org/10.1186/ISRCTN99715969
Secondary identifying numbers NT1101
Submission date
13/11/2007
Registration date
07/01/2008
Last edited
07/01/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mrs Tanja Effing
Scientific

Haaksbergerstraat 55
Poli 12
Enschede
7513 ER
Netherlands

Study information

Study designRandomised, active controlled, parallel group, two armed trial.
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymPULMOFIT-MST
Study objectivesChronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and mortality worldwide. Morbidity and mortality among COPD-patients are strongly related to acute exacerbations of COPD, which can be defined as sustained worsening of the patient’s condition, from stable state and beyond normal day-to-day variations, that is acute in onset and may warrant additional treatment in a patient with underlying COPD. Severe exacerbations may lead to hospital admissions and have a major impact on disease evolution and costs.

Pulmofit-MST, an immediate reactivation programme, will induce a reduction of the length of stay in the hospital, by preventing loss of peripheral muscle force and exercise capacity and thereby initiating a faster recovery of activities of daily living.
Ethics approval(s)Ethics approval received from the local medical ethics committee (Medisch Etische Toetsingscommissie Medisch Spectrum Twente) on the 16th January 2006 (ref: P06-05).
Health condition(s) or problem(s) studiedChronic Obstructive Pulmonary Disease (COPD)
InterventionThe protocol of the programme aimed at an active role of COPD-patients during their stay in the hospital. Patients in the intervention group were asked to perform three daily training sessions of 15 minutes each. One daily session was assisted by a physiotherapist, while the other two had to be performed by the patients themselves.

PULMOFIT-MST consists of four levels of increasing difficulty. Within four hours after admission, level I was started by the nurse who distributed the workbook with the description of all exercises and who instructed the first exercises to the patient. Within 24 hours after admission, the physiotherapist visited the patient and continued the programme by choosing the appropriate follow-up level and determining the intensity of the exercises. Every day the physiotherapist evaluated the exercises and the appropriateness of the training level and training intensity. A workbook functioned as a daily diary in which the intensities of training exercises were noted by the physiotherapist and daily experiences and improvements by the patient. All disciplines (chest physicians, nurses, and physiotherapists) stimulated patients to perform all three daily PULMOFIT-MST sessions.

Patients in the control group received usual care, meaning treatment the patients would have received prior to this study.

The duration of the treatment depends on the length of the hospitalisation. Patients of the intervention group are treated according to the PULMOFIT-MST protocol during the whole hospitalisation period.
Intervention typeOther
Primary outcome measureLength of hospital stay, defined as number of days between day of admission and day of medical discharge. Day of medical discharge was distinguished from the actual day of discharge because some patients remain in hospital longer than medically necessary (e.g. patients could not yet be referred to a nursing home).
Secondary outcome measures1. Walking distance (3 minutes walking test)
2. Dyspnoea (Borg scale)
3. Health status (Clinical COPD Questionnaire)
4. Activities of daily living (Barthel Index)
5. Readmissions due to a COPD-exacerbation (less than 28 days), measured at 28 days

Measurements take place at the day of admission, day 4 and the day of medical discharge.
Overall study start date01/02/2006
Completion date01/02/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants80
Key inclusion criteria1. A clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
2. A clinical diagnosis of an exacerbation of COPD for which hospitalisation was required
3. (Ex-) smoker
4. Age above 40 years
5. A life expectancy of at least 3 months
6. Able to understand and read Dutch
7. An informed consent from the subject prior to participation
Key exclusion criteria1. Pneumonia
2. Fever (greater than 38.5°C)
3. Severe confusion
4. Severe heart failure, New York Heart Association (NHYA) class III or IV
5. Relevant co-morbidity seriously influencing mobility
Date of first enrolment01/02/2006
Date of final enrolment01/02/2007

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Haaksbergerstraat 55
Enschede
7513 ER
Netherlands

Sponsor information

Dutch Asthma Foundation (The Netherlands)
Charity

Postbus 5
Leusden
3830 AA
Netherlands

ROR logo "ROR" https://ror.org/00ddgbf74

Funders

Funder type

Charity

Dutch Asthma Foundation (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan